HD-PLC-ALLIANCE
16.3.2021 07:02:09 CET | Business Wire | Press release
In order to integrate the latest improvements in speed and range of the HD-PLC*1 technology promoted by HD-PLC Alliance*2 , the Alliance has proposed the specifications of the next generation technology to the IEEE Standards Association*3 . To the great satisfaction of the Alliance members, recently published IEEE 1901-2020 Standard includes the latest HD-PLC features that provide higher speed, longer range wired communications over existing metal wires (control cable, coaxial cable, power cable, etc.).
Compared with wireless communication systems, HD-PLC enables more secure, stable and reliable communications. Furthermore, the use of existing cables allows a network infrastructure to cover not only indoors such as homes, buildings and factories but also outdoors extending several kilometers.
Mr. Yoshiyuki Miyabe, Senior Adviser of HD-PLC Alliance and Senior Managing Executive Officer of Panasonic Corporation, has sent a message, “Our company and HD-PLC Alliance have developed the HD-PLC technology cooperatively, which is now published as IEEE 1901-2020 standard. We anticipate this standardization will help make HD-PLC a breakthrough technology for the coming era of IoT. Making the most of this result for various products and business solutions for the future, we endeavor to further support innovation and advancement of the technology to provide new values to our customers.”
HD-PLC Alliance devotes its efforts to promote the technology through a certification program and logo. The test environment is being updated to offer the current third-generation communication compatibility services as well as upcoming fourth generation interoperability certification services compliant with IEEE 1901-2020.
On March 18, 2021, a webinar*4 on this technology will be held, organized by IEEE SA and HD-PLC Alliance. Also, please visit our renewed website.*5
Related Information:
HD-PLC Alliance members Press Release
[Panasonic Corporation]
Licensing IP Core for Semiconductors Complying with the IEEE 1901–2020 International Standard
https://news.panasonic.com/global/press/data/2021/03/en210316-2/en210316-2.html
[Socionext Inc.]
Socionext Agrees With MIRAIT, MMD, And Nuri Telecom On Next-Generation Long-Distance Power Line Communications For Verification And Social Implementation
https://www.socionext.com/en/pr/sn_pr20210309_01e.pdf
(Note) |
|
*1: |
HD-PLC™: A registered trademark or trademark of Panasonic Corporation in Japan and other countries. |
*2: |
HD-PLC Alliance: Established on September 25, 2007 with the aim to expand the use of High-definition Power Line Communication (HD-PLC) and to ensure communication compatibility. |
*3: |
IEEE Standards Association: Standards association within the Institute of Electrical and Electronics Engineers (IEEE) |
IEEE 1901-2020 standard: https://standards.ieee.org/standard/1901-2020.html |
|
*4: |
IEEE SA and HD-PLC Alliance Webinar March 2021 |
|
Subtitle: Home networking, Industrial and Building automation through HD-PLC (High-Speed Powerline Communication) |
Learn more: https://standards.ieee.org/events/index.html |
|
*5: |
HD-PLC Alliance Homepage: https://hd-plc.org/ |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005273/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom